España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
PTC Therapeutics
PTCT
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$46.24
0.99
2.19%
At close: -
$46.24
0.00050
0.00%
After Hours: Dec 20, 4:01 PM EDT
Get Report
Comment
PTC Therapeutics (PTCT) Forecast
News
Earnings
PTC Therapeutics (PTCT) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics Stock (NASDAQ: PTCT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, December 19, 2024
PTC Therapeutics Submits NDA To FDA For Vatiq...
Benzinga Newsdesk
Friday, December 13, 2024
Morgan Stanley Upgrades PTC Therapeutics to O...
Benzinga Newsdesk
Friday, December 06, 2024
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
Vandana Singh
Wednesday, December 04, 2024
Citigroup Maintains Sell on PTC Therapeutics,...
Benzinga Newsdesk
Goldman Sachs Maintains Sell on PTC Therapeut...
Benzinga Newsdesk
Tuesday, December 03, 2024
UBS Maintains Buy on PTC Therapeutics, Raises...
Benzinga Newsdesk
Bank of America To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Tuesday
Avi Kapoor
Baird Maintains Outperform on PTC Therapeutic...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on PTC Therap...
Benzinga Newsdesk
Monday, December 02, 2024
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
Vandana Singh
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Avi Kapoor
PTC Therapeutics shares are trading higher af...
Benzinga Newsdesk
PTC Therapeutics Signed An Exclusive Global L...
Benzinga Newsdesk
PTC Therapeutics Signs Exclusive Global Licen...
Benzinga Newsdesk
Wednesday, November 27, 2024
Baird Maintains Outperform on PTC Therapeutic...
Benzinga Newsdesk
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
Vandana Singh
PTC Therapeutics Enters Into Agreement To Sel...
Benzinga Newsdesk
Tuesday, November 26, 2024
PTC Therapeutics Says CardinALS Trial Of Utre...
Benzinga Newsdesk
PTC Therapeutics shares are trading higher af...
Benzinga Newsdesk
Wells Fargo Maintains Overweight on PTC Thera...
Benzinga Newsdesk
Tuesday, November 19, 2024
JP Morgan Maintains Overweight on PTC Therape...
Benzinga Newsdesk
Thursday, November 14, 2024
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain
Vandana Singh
Barclays Maintains Equal-Weight on PTC Therap...
Benzinga Newsdesk
Reported Earlier, PTC Therapeutics Secures FD...
Benzinga Newsdesk
Monday, November 11, 2024
Barclays Maintains Equal-Weight on PTC Therap...
Benzinga Newsdesk
Friday, November 08, 2024
PTC Therapeutics shares are trading higher af...
Benzinga Newsdesk
Baird Maintains Outperform on PTC Therapeutic...
Benzinga Newsdesk
Thursday, November 07, 2024
PTC Therapeutics Sees FY24 Revenue $750M-$800...
Benzinga Newsdesk
PTC Therapeutics Q3 2024 GAAP EPS $(1.39) Bea...
Benzinga Newsdesk
Wednesday, November 06, 2024
Earnings Preview For PTC Therapeutics
Benzinga Insights
Wednesday, October 30, 2024
PTC Therapeutics Announced That The U.S. Food...
Benzinga Newsdesk
Friday, October 18, 2024
PTC Therapeutics Says CHMP Of European Medici...
Benzinga Newsdesk
Monday, October 14, 2024
PTC Therapeutics Reports FDA Sets Target Regu...
Benzinga Newsdesk
Friday, October 11, 2024
Morgan Stanley Maintains Equal-Weight on PTC ...
Benzinga Newsdesk
Tuesday, October 08, 2024
Baird Reiterates Outperform on PTC Therapeuti...
Benzinga Newsdesk
PTC Therapeutics shares are trading higher af...
Benzinga Newsdesk
PTC Therapeutics Announces Updates On Vatiqui...
Benzinga Newsdesk
Friday, October 04, 2024
RBC Capital Maintains Sector Perform on PTC T...
Benzinga Newsdesk
Tuesday, October 01, 2024
PTC Therapeutics Announces FDA Acceptance For...
Benzinga Newsdesk
Thursday, September 26, 2024
FDA Grants Fast Track Designation To PTC Ther...
Benzinga Newsdesk
Friday, September 20, 2024
Cantor Fitzgerald Reiterates Overweight on PT...
Benzinga Newsdesk
Tuesday, September 17, 2024
Cantor Fitzgerald Reiterates Overweight on PT...
Benzinga Newsdesk
Wednesday, September 04, 2024
Baird Initiates Coverage On PTC Therapeutics ...
Benzinga Newsdesk
Wednesday, August 21, 2024
Cantor Fitzgerald Reiterates Overweight on PT...
Benzinga Newsdesk
Friday, August 09, 2024
Cantor Fitzgerald Maintains Overweight on PTC...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on PTC Therap...
Benzinga Newsdesk
Thursday, August 08, 2024
PTC Sees FY24 Revenue $700M-$750M Vs $749M Es...
Benzinga Newsdesk
PTC Therapeutics Q2 2024 GAAP EPS $(1.29) Mis...
Benzinga Newsdesk
Tuesday, July 30, 2024
PTC Therapeutics Submits Sepiapterin NDA To F...
Benzinga Newsdesk
Tuesday, July 16, 2024
Cantor Fitzgerald Reiterates Overweight on PT...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch